Home > Oncology > ASCO 2020 > Breast & Ovarian Cancer > PHOEBE, a phase 3 trial comparing pyrotinib and lapatinib in HER2-positive metastatic breast cancer

PHOEBE, a phase 3 trial comparing pyrotinib and lapatinib in HER2-positive metastatic breast cancer

Presented By
Dr Binghe Xu, Peking Union Medical College, China
Conference
ASCO 2020
Trial
Phase 3, PHOEBE
The open-label, multicentre, randomised, phase 3 PHOEBE study compared pyrotinib plus capecitabine versus lapatinib plus capecitabine in metastatic HER2-positive breast cancer patients. Results showed an improvement in progression-free survival (PFS) and multiple secondary endpoints. The pyrotinib combination therapy is now approved in China as second-line standard-of-care for this patient group. Pyrotinib is a small-molecular, irreversible, pan-ErbB receptor kinase inhibitor targeting EGFR, HER2, and HER4 [1]. In previous phase 2 and phase 3 studies, pyrotinib in combination with capecitabine has shown clinically meaningful benefits and tolerability on patients with metastatic HER2-positive breast cancer after prior treatment with taxanes, anthracyclines, and/or trastuzumab. Pyrotinib plus capecitabine showed better overall response rates (ORR) and PFS compared with lapatinib plus capecitabine, which was standard second line of care for these patients in ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on